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ABSTRACT Human and chimpanzee adenovirus vectors are being developed to cir-
cumvent preexisting antibodies against common adenovirus vectors such as Ad5.
However, baseline immunity to these vectors still exists in human populations. Tradi-
tional cloning of new adenovirus vaccine vectors is a long and cumbersome process
that takes 2 months or more and that requires rare unique restriction enzyme sites.
Here we describe a novel, restriction enzyme-independent method for rapid cloning
of new adenovirus vaccine vectors that reduces the total cloning procedure to 1
week. We developed 14 novel adenovirus vectors from rhesus monkeys that can be
grown to high titers and that are immunogenic in mice. All vectors grouped with
the unusual adenovirus species G and show extremely low seroprevalence in hu-
mans. Rapid cloning of novel adenovirus vectors is a promising approach for the de-
velopment of new vector platforms. Rhesus adenovirus vectors may prove useful for
clinical development.
IMPORTANCE To overcome baseline immunity to human and chimpanzee adenovi-
rus vectors, we developed 14 novel adenovirus vectors from rhesus monkeys. These
vectors are immunogenic in mice and show extremely low seroprevalence in hu-
mans. Rhesus adenovirus vectors may prove useful for clinical development.
KEYWORDS adenoviruses, live vector vaccines, rhesus monkey, vaccines
Recombinant adenovirus (Ad) vaccine vectors are being explored for pathogens anddiseases such as human immunodeﬁciency virus (HIV), tuberculosis (TB), Zika virus,
malaria, respiratory syncytial virus (RSV), and Ebola as well as for cancer (1–7). Adeno-
virus vectors with low global seroprevalence are desirable to avoid potential problems
associated with baseline antivector immunity and to achieve optimal immune re-
sponses and dose control following vaccination (8–14). Rare human and chimpanzee
adenoviruses are being explored as vaccine vectors (15), but due to their close
phylogenetic proximity to common human serotypes, substantial seroprevalence is
still detected in human populations, particularly in the developing world (16, 17). In
contrast, with greater evolutionary distance from human Ads, rhesus monkey Ads
would be expected to have lower seroprevalence in human populations (18). Moreover,
adenovirus species can induce distinct innate immune response proﬁles, and thus
different adenovirus vectors may prove most suitable for speciﬁc applications (19–22).
Various methods to clone and to vectorize new serotypes exist (11, 12, 14, 23). All
current methods rely on the rare availability of restriction enzyme sites in the large
genome of adenovirus, and to date the most efﬁcient protocol requires at least 2
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months of complex cloning (23). With the advancement of new molecular techniques
(24), we describe here a novel and rapid method of constructing adenovirus vectors.
This method is independent of restriction enzymes, requires far less starting material,
and can be applied essentially to any adenovirus serotype.
We report here the construction and characterization of 14 novel rhesus adenovirus
(RhAd) vectors that were generated by Gibson assembly (24). This novel approach to
the rapid development of Ad vaccine vectors and the biological assessment of these
new RhAd vectors substantially increase the available vectors for vaccination and gene
therapy.
RESULTS
Virus isolation. We previously reported the construction of 3 rhesus adenovirus
vectors (RhAd51, RhAd52, and RhAd53) (14). We now report the isolation of 14
additional novel adenoviruses from stool ﬁltrates of 13 rhesus monkeys. Plaque-
puriﬁed viruses were expanded, and viral DNA was sent out for whole-genome 454
sequencing (Seqwright GE Healthcare, Houston, TX). All viruses proved novel and were
termed RhAd54 to RhAd67. Whole-genome sequences were then analyzed by maxi-
mum likelihood phylogenetic trees (25, 26). All novel rhesus adenoviruses grouped with
the poorly deﬁned species G, with the majority of differences observed in the hexon
(Fig. 1A and B). The genomic structure of RhAds proved similar to that of human Ad5,
except that RhAds encoded 2 or 3 ﬁbers, whereas most human and chimpanzee Ads
encode 1 or 2 ﬁbers (Fig. 1C) (27).
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FIG 1 Phylogenetic analysis. Maximum likelihood phylogenetic trees for rhesus, human, and chimpanzee adenovirus for complete genomes (A) and hexon
genes (B) were generated using PhyML 3.1/3.0 aLRT. DNA sequences were aligned and placed into a tree with TreeDyn 198.3. The trees are drawn to scale, with
branch lengths measured in the number of substitutions per site. (C) Schematic representation of the placement of ﬁber genes in relation to the locations of
the E1, E3, and E4 regions, not drawn to scale.
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Vector construction. We next used Gibson assembly cloning techniques to con-
struct adenovirus vectors. The Gibson cloning method (24) utilizes 20- to 60-bp DNA
overhangs of adjacent double-stranded DNA fragments. In a single reaction, 5=-
exonuclease generates 3= single-stranded matching overhangs that anneal together
and are repaired by polymerase and ligase. For vector construction, the complete
rhesus adenovirus genomes were divided into fragments that were assembled into an
E1-deleted AdApter plasmid, containing the left inverted terminal repeat (ITR) through
pIX and pIVa2 sequences, and an E3-deleted cosmid that contains the pIX through the
right ITR (Fig. 2A). For each of these constructs, the genome was divided into shorter
fragments and ampliﬁed by PCR (Fig. 2B). Assembled constructs were transformed into
Escherichia coli, and colonies were screened (Fig. 2C and D). Cloning of a novel RhAd
vector took an average of 1 week to complete from wild-type adenovirus genome into
E1/E3 deleted plasmids, which we used directly in transfections to obtain recombinant
vector growth. Included in this cloning was the introduction of a transgene cassette
with or without a transgene, such as enhanced green ﬂuorescent protein (eGFP),
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FIG 2 Adenovirus vector construction. (A) Schematic representation of adenovirus whole-genome fragments generated by PCR for
assembly into the AdApter plasmid and cosmid. Matching overhangs of adjacent PCR fragments are indicated by matched patterns. (B)
Representative gel pictures of the PCR fragments that are used to assemble the ﬁnal constructs. (C and D) Screening of AdApter plasmid
(C) and cosmid (D) by restriction enzyme digestion with HincII and BsrGI, respectively, reveals a higher percentage of positive clones for
the AdApter plasmid than for the cosmid. Positive clones with expected banding patterns are boxed.
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luciferase, or simian immunodeﬁciency virus gag (SIVgag). The use of high-ﬁdelity
polymerases generally yielded PCR fragments free from unintended mutations, but
overlapping junction regions that recombine during Gibson assembly were more error
prone, with mutations observed in 10 to 20% of the constructs. The ﬁnal selected vector
plasmids and cosmids were veriﬁed by sequencing to match the wild-type genome.
Novel RhAd vector constructs were transfected in E1-complementing cells, and vector
batches were produced as previously described (12). We produced puriﬁed batches of
all RhAd vectors except RhAd67, which we were unable to purify due to aggregation
of virus particles (vp) using our standard puriﬁcation protocol.
Seroprevalence. Seroprevalence in both human and rhesus monkey populations
was determined using luciferase-based neutralization assays as previously described
(28). Seroprevalence was assessed in human populations from South Africa (n  100)
and Rwanda (n  100) as well as in naive rhesus monkeys (n  107) (Fig. 3 and Table
1). All RhAd vectors developed here exhibited extremely low seroprevalence in these
human populations with titers of 36 in 76 to 98% of individuals and titers of 200 in
94 to 99% of individuals. In contrast, for human Ad5, only 10% exhibited titers of 36,
67% had titers of 200, and 43% had high titers, of 1,000. Human Ad26 and
chimpanzee Ad24 demonstrated intermediate titers, with 27 to 40% exhibiting titers of
36 and 40 to 45% having titers between 36 and 200, consistent with prior reports (29).
In contrast, the RhAd vectors showed higher seroprevalence than the human and
chimpanzee Ad vectors in rhesus monkeys, as expected.
Immunogenicity. We next evaluated the immunogenicity of this panel of RhAd
vectors expressing the SIVgag antigen. SIVgag-speciﬁc cellular immune responses were
assessed in mice using Db/AL11 tetramer binding assays (30). C57BL/6 mice (n 
8/group) were immunized once with 108 or 109 vp of Ad vectors expressing SIVmac239
Gag, and Db/AL11-speciﬁc CD8 T-cell responses in peripheral blood mononuclear
cells (PBMCs) were assessed weekly. All RhAd vectors were immunogenic at both doses,
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FIG 3 Seroprevalence. Seroprevalence to the RhAd vectors was determined in 200 human serum samples
from South Africa and Rwanda (A) and 107 SIV-naive rhesus monkeys (B). Titers are graphed as the
dilution at which 90% of virus gets neutralized by antibodies present in the serum. The assay sensitivity
cutoff is a dilution of 36.
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with no signiﬁcant differences compared to Ad5 (one-way analysis of variance [ANOVA]
with Bonferroni corrections) (Fig. 4A). Peak responses for the RhAds were generally
observed on day 14 compared to day 21 for Ad5. Additionally, we assessed effector and
memory precursor differentiation as well as exhaustion of Db/AL11-speciﬁc CD8 T
cells by gating on cell markers KLRG1, CD127, and PD-1, respectively (31, 32). For the
RhAd vectors, high levels of antigen-speciﬁc effector precursor CD8 T cells, indicated
by increased expression of KLRG1, were seen at day 14 after immunization (Fig. 4B).
These levels declined by day 28, at which time a larger memory precursor population
was established, indicated by increased CD127 expression. In contrast, Ad5 has been
shown to persist in the effector phenotype, similar to what we observed here (31, 33).
Furthermore, the RhAds showed lower programmed cell death 1 (PD-1) expression on
the Db/AL11-speciﬁc CD8 T cells than did Ad5 (Fig. 4C), a marker associated with
exhaustion (32).
We next assessed the functionality of the responses generated by performing
enzyme-linked immunosorbent spot (ELISPOT) assays in splenocytes in response to the
complete SIVgag peptide pool, the CD8 T-cell dominant epitopeAL11 and subdomi-
nant epitope KV9, and the CD4 T-cell subdominant epitope DD13 as a potential
measure of efﬁcacy as vaccine vector. Splenocytes were isolated 28 days postvaccina-
tion (12). All RhAd vectors demonstrated robust responses with nonsigniﬁcant variance
among the different RhAd vectors by one-way ANOVA with Bonferroni correction (Fig.
4D). RhAd55, -61, and -62 showed the lowest CD8 T-cell responses, and RhAd51, -52,
-54, -59, and -66 showed the highest CD8 T-cell responses. Ad5 and RhAd52 induced
the strongest responses to the subdominant CD8 T-cell epitope KV9, whereas RhAd63
elicited the highest response to the CD4 T-cell epitope DD13.
Tissue tropism and cellular receptors. We next assessed tissue tropism and
receptor use in vitro. Human immortalized cell lines ARPE-19 (retinal), HuTu80 (duode-
num adenocarcinoma), and A549 (lung carcinoma) and human primary bladder and
prostate cell lines, as well as the rhesus cell line MK2 (kidney), were infected at a
multiplicity of infection (MOI) of 100 or 1,000 virus particles per cell for 24 h with vectors
expressing eGFP and analyzed by ﬂow cytometry. RhAd54 expressing eGFP led to
several unsuccessful productions due to unknown reasons and was omitted from
tropism and receptor testing. MK2 and ARPE-19 cells were transduced most efﬁciently
for all vectors (Fig. 5A and B). HuTu80 duodenum adenocarcinoma cells were trans-
duced most efﬁciently by RhAd56, -57, -62, and -66, whereas A549 lung carcinoma cells
were transduced best by RhAd56, -57, -59, and -62. Human primary bladder cells were
TABLE 1 Seroprevalence and receptor afﬁnitya
Adenovirus
Seroprevalence (%) at indicated titers
Receptor
Human Monkey
<36 36–200 201–1,000 >1,000 <36 36–200 201–1,000 >1,000
Ad5 10.4 22.2 24.3 43.1 99.1 0.9 0.0 0.0 CAR
Ad26 27.1 45.8 20.8 6.3 98.2 1.9 0.0 0.0 CD46
ChAd24 55.0 40.0 4.0 1.0 95.4 4.6 0.0 0.0 CD46
RhAd51 93.8 2.8 2.1 1.4 77.8 15.7 6.5 0.0 CAR
RhAd52 84.7 11.1 1.4 2.8 54.6 31.5 9.3 4.6 Unknown
RhAd53 90.3 3.5 5.6 0.7 96.3 1.9 0.9 0.9 Unknown
RhAd54 95.0 3.5 1.0 0.5 83.8 14.1 2.0 0.0 Unknown
RhAd55 91.5 6.5 1.5 0.5 62.6 25.2 12.2 0.0 CAR
RhAd56 88.9 7.6 2.1 1.4 81.5 15.7 2.8 0.0 Unknown
RhAd57 83.5 11.0 3.5 2.0 63.6 24.2 12.1 0.0 CAR
RhAd58 92.5 4.5 2.0 1.0 66.7 22.9 10.5 0.0 CAR
RhAd59 85.5 9.5 3.5 1.5 72.3 19.2 8.5 0.0 CAR
RhAd60 75.5 18.0 6.0 0.5 71.7 17.9 7.6 2.8 CAR/unknown
RhAd61 93.0 5.5 1.5 0.0 73.7 23.2 3.0 0.0 CAR
RhAd62 83.0 15.0 1.5 0.5 80.2 14.2 6.6 0.0 CAR
RhAd63 96.0 3.5 0.0 0.5 61.6 26.3 12.1 0.0 Unknown
RhAd64 97.5 1.5 1.0 0.0 88.9 10.1 1.0 0.0 CAR/unknown
RhAd65 97.0 1.0 1.5 0.5 64.7 24.2 11.1 0.0 CAR/unknown
RhAd66 93.0 4.5 1.0 1.5 80.0 12.0 7.0 1.0 Unknown
aSeroprevalence to the novel rhesus adenovirus vectors was assessed in sub-Saharan human sera and in SIV-
naive monkey sera. Receptor binding was assessed using the HAP1 parental and CAR, CD46, CD55, and
CMAS knockout cell lines.
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optimally transduced by RhAd52, -53, -56, -59, -60, and -62, whereas primary prostate
cells were infected most efﬁcient by RhAd56, -57, -59, and -62.
Human adenoviruses often use the Coxsackie-adenovirus receptor (CAR) or CD46 as
a primary cellular entry receptor (34). To assess receptor use by these RhAds, we used
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parental HAP1 cells as well as CAR, CD46, CD55, and sialic acid (CMAS) receptor
knockout (KO) cell lines (Horizon). Cells were infected for 1 h with Ad vectors expressing
eGFP. After 24 h, cells were harvested and analyzed for eGFP positivity (Fig. 5C and
Table 1). All values were normalized to 100% infection in parental HAP1 cells. Human
Ad5 uses CAR as its primary cellular entry receptor (34), which was conﬁrmed here by
the blockade of entry into the CAR KO cell line. Human Ad35 uses CD46 (34), as shown
here by the blockade of entry into the CD46 KO cell line. RhAds 51, 55, 57, 58, 59, 61,
and 62 were completely blocked from entry into the CAR KO cell line, suggesting that
CAR is their primary cell entry receptor. Partial block into CAR KO cells was observed for
RhAds 60, 64, and 65, whereas minimal to no effect by CAR KO cells was seen for RhAds
52, 53, 56, 63, and 66. CD46 and CD55 did not appear to be used by any of the RhAd
vectors, and minor effects were observed for all vectors in the sialic acid KO cells.
RhAds 52, 53, 56, 63, and 66 were able to infect all of these cell lines, suggesting that
they utilize other cell entry receptors.
DISCUSSION
In this study, we describe the isolation, construction, and characterization of 14
novel rhesus adenovirus vectors. We adapted Gibson assembly techniques for the rapid
construction of these vectors. This method reduced the time of construction from over
2 months (23) to approximately 1 week and is generalizable and independent of
restriction enzyme sites. These novel RhAd vectors exhibited very low seroprevalence
in human populations and proved highly immunogenic in mice.
We previously reported the construction of 3 novel RhAd vectors (RhAd51, RhAd52,
and RhAd53) (14) and have demonstrated the short-term and durable protective
efﬁcacy of RhAd52 expressing ZIKV.M-Env against Zika virus (ZIKV) challenge in rhesus
monkeys (7, 40). The present work substantially expands this class of vectors. Similar to
RhAd51 to RhAd53, all 14 RhAds described here grouped with the poorly characterized
species G, which is separate from nearly all the human and chimpanzee adenoviruses.
Sequence analyses of the RhAd viral genomes identiﬁed an overall similar genome
organization compared to existing human and chimpanzee adenoviruses, with the
major genetic differences seen within the late genes that express the hexon, ﬁber,
and penton proteins (16, 19–21, 29, 35–37). Interestingly, whereas the majority of
human adenoviruses have a single ﬁber gene, all the rhesus adenoviruses described
here have two or three different ﬁber genes. The extra ﬁber genes could potentially
broaden the tissue tropism and immune responses; however, this remains to be
determined.
Consistent with the larger phylogenetic distance from human Ads, all RhAd
vectors showed very low seroprevalence in sub-Saharan African human sera compared
to other human and chimpanzee Ad vectors, conﬁrming previous ﬁndings with other
RhAds (14). In addition, a single dose of these RhAd vectors expressing SIVgag proved
highly immunogenic in mice with antigen-speciﬁc responses comparable to those of
other human and chimpanzee Ad vectors. The SIVgag-speciﬁc CD8 T-cell responses
induced by the RhAd vectors were less exhausted and led to a larger memory precursor
phenotype than Ad5, which may contribute to improved recall responses following
boosting (31, 32).
Phenotypic differences among the various RhAd vectors were observed when
assessing tropism and receptor afﬁnity. These RhAd vectors showed tropism for human
cells with some variation among vectors. Nine of 16 RhAds used CAR as a primary
cellular entry receptor, but additional receptors also likely exist. These differences may
be relevant for the applicability of these RhAd vectors if speciﬁc tissues need to be
targeted.
In conclusion, we have substantially expanded the portfolio of rhesus adenovirus
vectors using a novel rapid cloning method. These RhAd vectors are all part of species
G and show characteristics of seroprevalence and immunogenicity that make them
attractive as vaccine and gene transfer vectors.
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MATERIALS AND METHODS
Virus isolation and vector construction. Rhesus adenoviruses were isolated from stool samples
essentially as previously described (14). Brieﬂy, rhesus monkey stool samples were shown to contain
adenovirus by metagenomics sequencing. E1-complementing cells, also used for growth of replication-
incompetent vectors, were infected with ﬁltered stool samples and monitored for adenoviral growth.
Lysates were plaque puriﬁed twice, and single clones were expanded and puriﬁed by cesium chloride
density centrifugation. Viral DNA was extracted by lysing puriﬁed virus with SDS and proteinase K
treatment and was sequenced by 454 sequencing (Seqwright GE Healthcare, Houston, TX).
To clone vectors, the wild-type genome was divided into two constructs. The ﬁrst construct, the
AdApter plasmid, consisted of the left ITR of the adenovirus genome with deletion of all E1 sequences
and approximately 2.5 kb from pIX, including the transcriptional elements necessary for pIX expression
(38). The E1 region was replaced by a transgene cassette, which contains a cytomegalovirus (CMV)
promoter, multiple cloning site, and simian virus 40 (SV40) poly(A) tail. The second construct, the cosmid,
which supports stable replication of large DNA constructs, consists of the remainder of the adenovirus
genome from the pIX to the end of the right ITR. In the cosmid, the E3 region was deleted, and the start
at the pIX region created a 2.5-kb overlap with the AdApter plasmid that facilitated homologous
recombination in transfected E1-complementing cells.
The AdApter and cosmid primers were designed to generate 4 or 6 DNA fragments, respectively. Each
PCR fragment had a 20- to 30-bp overlap with its adjacent PCR fragment. The PCR samples were run on
a 0.8% low-melting-temperature agarose gel and puriﬁed using the Gel DNA recovery kit (Zymo
Research, CA). DNA was eluted in nuclease-free water, and the concentration was determined using the
Nanodrop 2000 spectrophotometer (Thermo Scientiﬁc, MA). The PCR fragments were assembled to-
gether (24) using the Gibson assembly master mix kit (NE Biolabs, MA) according to the manufacturer’s
recommendations and transformed into DH10B T1 phage-resistant electrocompetent E. coli (Invitrogen,
CA). Colonies were screened by restriction enzyme digests, and band patterns were analyzed by DNA
agarose gel electrophoresis and Sanger sequencing (Harvard core facility, Boston, MA).
Vector growth. Commercially available E1-complementing cell lines were transfected by Lipo-
fectamine with linearized AdApter plasmid and cosmid (14). Homologous recombination yielded full-
length, E1/E3-deleted adenovirus. Virus was plaque puriﬁed and expanded to production followed by
puriﬁcation by cesium chloride density centrifugation. Puriﬁed virus was buffer exchanged into
phosphate-buffered saline (PBS) with 5% (vol/vol) sucrose buffer, ﬂash frozen, and stored at 80°C. The
infectivity of the puriﬁed virus was assessed by PFU assays, and intact transgene presence was conﬁrmed
by PCR and sequencing.
Phylogenetic analysis. DNA sequences for whole genome and hexon were aligned by Muscle using
ClustalW (EMBL-EBI, Hinxton). Maximum likelihood trees were generated using PhyML 3.1/3.0 aLRT with
substitution model HKY85 and Gblock alignment reﬁnement (Phylogeny.fr). TreeDyn 198.3 was used for
visualization.
Seroprevalence. Seroprevalence of the novel rhesus adenovirus vectors was assessed by luciferase-
based virus neutralization assays as previously described (28). Brieﬂy, 100 South African and 100
Rwandan serum samples as well as 107 naive rhesus monkey serum samples were tested. Human
samples were obtained with informed consent, and seroprevalence studies were performed with Beth
Israel Deaconess Medical Center institutional review board (IRB) approval. Serum was serially diluted in
a 96-well plate, with the exception that the last column served as maximum infectivity, which was used
for normalization for each RhAd vector. Virus was added, which was followed by addition of A549 cells.
The plates were incubated for 24 h before the medium was removed, and 100 l PBS and 100 l
Steady-Glo substrate in lysis buffer (Promega, WI) were added to the wells according to the manufac-
turer’s recommendations. Luminescence was read on a Victor 3 multilabel counter (PerkinElmer, MA). The
seroprevalence titer was determined to be the dilution of serum at which 90% of the virus was
neutralized in the presence of serum.
Adaptive immune responses. To assess the cellular immunogenicity of these novel rhesus monkey
adenovirus vectors, wild-type C57BL/6 mice (n  8) were immunized once by the intramuscular (i.m.)
route with 109 or 108 vp of vectors expressing simian immunodeﬁciency virus (SIV) mac239 Gag. SIV
Gag-speciﬁc CD8 T lymphocytes were assessed at weekly intervals by major histocompatibility complex
class I-restricted Db/AL11 tetramer binding assays as previously described (30). Included in the tetramer
binding assays were KLRG1, CD127, and PD-1 detection antibodies. Further assessment was done using
gamma interferon (IFN-) enzyme-linked immunosorbent spot (ELISPOT) assays with splenocytes from
spleens harvested at day 28. Splenocytes were isolated and stimulated in vitro with a SIV mac239 Gag
peptide pool, the CD8 T-lymphocyte epitopes AL11 (AAVKNWMTQTL) and KV9 (KSLYNTVCV), and the
CD4 T-lymphocyte epitope DD13 (DRFYKSLRAEQTD), as described previously (39). Results reﬂect those
from at least two separate experiments. All animal studies were approved by the Beth Israel Deaconess
Medical Center Institutional Animal Care and Use Committee (IACUC).
Vector tropism. Tissue tropism was assessed by infection of RhAd-eGFP-expressing vectors in the
following cell lines (all from ATCC): A549 (human lung carcinoma), MK2 (rhesus kidney), ARPE-19 (human
retinal), HuTu80 (human duodenum), prostate (human primary cells), and bladder (human primary cells).
Cells (105) were seeded in an MW24 plate and incubated overnight at 37°C, 10% CO2. The next day, cells
were infected (n  2) with adenovirus vectors (MOI, 100 and 1,000) and incubated overnight. After 24
h, cells were harvested and ﬁxed in 2% formaldehyde (Sigma) and run and analyzed on an LRSII ﬂow
cytometer and FlowJo software v8 (BD Biosciences). Assays were run a minimum of two times, and
percentage-positive cells were plotted using Graphpad prism 7 (Graphpad).
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Receptor use. To assess receptor use of these novel rhesus adenovirus vectors, we utilized HAP1
parental as well as CAR, CD46, CD55, and sialic acid knockout cell lines (Horizon). One day prior to
infection, 105 cells were seeded in an MW24 plate. The next day, the cells were infected (n  2) with
adenovirus vectors (MOI, 1,000) expressing eGFP for 1 h. After 1 h, medium was replaced with fresh
medium, and the cells were incubated for 24 h, at which time the cells were harvested, ﬁxed in 2%
formaldehyde, and analyzed by ﬂow cytometry using an LSRII ﬂow cytometer and FlowJo software v8 (BD
Biosciences). Assays were run a minimum of two times. Results were normalized for 100% infection in the
parental cell line and plotted using Graphpad prism 7 (Graphpad).
Accession number(s). The sequences of the 14 novel viruses, termed RhAd54 to RhAd67, have been
submitted to GenBank under accession numbers MF198448 to MF198461.
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